PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|June 14, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-05-2017
- Volume 12
- Issue 7
Rentschler Biotechnologie and Rentschler Fill Solutions Partner on Fill/Finish
Author(s)Pharmaceutical Technology Editors
The companies are partnering to provide new fill/finish facilities and solutions for biopharmaceutical products.
Advertisement
On June 13, 2017, Rentschler Biotechnologie GmbH and Rentschler Fill Solutions GmbH announced a strategic partnership to provide new fill/finish facilities and solutions for biopharmaceutical products. Under the terms of the agreement, Rentschler Fill Solutions will serve as the exclusive partner for the fill/finish services of Rentschler Biotechnologie’s manufacturing projects. Rentschler Fill Solutions is owned by the Rentschler family and will begin operations in mid-2018. In addition to servicing Rentschler Biotechnologie’s clients, Rentschler Fill Solutions will offer its fill/finish services on a clinical as well as commercial scale to its own client base.
The company will employ advanced aseptic filling technology at the Rentschler Fill Solutions facility in Austria. The filling technology will be able to fill up to 60,000 vials per batch. Timelines and batch sizes can be tailored and flexibly scaled. The Rentschler Fill Solutions facility complies with all required regulatory standards and is designed to enable future expansion without interrupting ongoing operations.
Rentschler Biotechnologie and Rentschler Fill Solutions will introduce their partnership and service offering at the BIO International Convention from June 19–22 in San Diego, CA.
Source: Rentschler
Articles in this issue
about 9 years ago
Overcoming Concerns to Adopting Continuous Processesabout 9 years ago
The Search for Efficient Synthesis of Complex Cannabinoidsover 9 years ago
BASF Ups Ibuprofen Capacities in Germany and North Americaover 9 years ago
Itzhak Krinsky Joins Halo Pharma Board of Directorsover 9 years ago
Survey Reveals that Blockchain will be Adopted Within Five YearsAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement